The $2 peak was when they first tried to commercialise Colostat. The clinical trial results were amazing, it looked good! They applied for TGA approval, but withdrew the application because the kit manufacturing process (French company) wasn’t refined enough. Now they have a new vastly more experienced CEO and a new American manufacturer. A lot of work has been done. The commercial pathway later this year will be the well trodden ‘lab developed test’, not via TGA at first…
I get the sense the share price is it’s suffering from ‘once bitten twice shy’
Ann: ColoSTAT Beta kit verification and validation update, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
-0.005(4.55%) |
Mkt cap ! $29.82M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.0¢ | 9.9¢ | $235.5K | 2.274M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 66620 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 251207 | 3 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| RHY (ASX) Chart |